Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Vistagen Therapeutics Inc’s stock clocked out at $4.02, up 1.52% from its previous closing price of $3.96. In other words, the price has increased by $1.52 from its previous closing price. On the day, 0.53 million shares were traded. VTGN stock price reached its highest trading level at $4.1799 during the session, while it also had its lowest trading level at $3.94.
Ratios:
To gain a deeper understanding of VTGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.98 and its Current Ratio is at 5.98. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 07, 2023, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $30.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTGN now has a Market Capitalization of 123335496 and an Enterprise Value of 62511492. For the stock, the TTM Price-to-Sale (P/S) ratio is 176.19 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 96.767 whereas that against EBITDA is -1.051.
Stock Price History:
The Beta on a monthly basis for VTGN is 0.54, which has changed by 0.33112586 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, VTGN has reached a high of $4.25, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 22.69%, while the 200-Day Moving Average is calculated to be 47.44%.
Shares Statistics:
It appears that VTGN traded 548.48K shares on average per day over the past three months and 473840 shares per day over the past ten days. A total of 29.28M shares are outstanding, with a floating share count of 27.73M. Insiders hold about 9.63% of the company’s shares, while institutions hold 55.81% stake in the company. Shares short for VTGN as of 1757894400 were 1161410 with a Short Ratio of 2.12, compared to 1755216000 on 607798. Therefore, it implies a Short% of Shares Outstanding of 1161410 and a Short% of Float of 6.17.
Earnings Estimates
The market rating for Vistagen Therapeutics Inc (VTGN) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.25 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.33 and -$1.62 for the fiscal current year, implying an average EPS of -$1.48. EPS for the following year is -$1.5, with 3.0 analysts recommending between -$1.39 and -$1.71.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for VTGN’s current fiscal year. The highest revenue estimate was $1.7M, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $577k. In the same quarter a year ago, actual revenue was $486k
